(Health Korea News / Lee Si-woo) Hanmi Pharmaceutical, which is attracting attention as the cradle of research and development (R&D) in the Korean pharmaceutical industry, received a Prime Minister’s Award from the government in recognition of its contribution to actively practicing social responsibility through sustainable management.
Hanmi Pharmaceutical (CEO and President Park Jae-hyeon) received the Prime Minister’s Award for National Quality Special Award and the Prime Minister’s Award for Sustainable Management at the ’50th National Quality Management Conference’ held at COEX in Seoul on the 20th, hosted by the National Agency for Technology and Standards of the Ministry of Trade, Industry and Energy and organized by the Korean Standards Association. Awarded.
The National Quality Management Competition is the largest and most authoritative quality promotion event in the domestic industry. It discovers and awards meritorious people and excellent companies that have led industrial development and strengthened national status through quality management every year.
Hanmi Pharmaceutical has been the first in the domestic pharmaceutical industry to publish a report containing sustainable innovation management goals and achievements, and has proactively recognized the importance of sustainable management and established a dedicated organization called ‘ESG Group’. Through this, the company received high praise for systematically implementing sustainability management plan establishment, operation, evaluation, and feedback activities.
In addition, based on a materiality assessment that reflects the characteristics of pharmaceutical companies, we are establishing an ESG management strategy and a mid- to long-term roadmap to present future directions, and are continuing to make multifaceted efforts, such as introducing an international certification system to strengthen the sustainable management system.
“Hanmi Pharmaceutical’s top management clearly recognizes fulfillment of social responsibility”
In particular, Hanmi Pharmaceutical’s top management received great praise for clearly recognizing that ‘a company’s sustainable growth is based on fulfilling social responsibilities and coexistence with stakeholders.’
The review committee said, “Hanmi Pharmaceutical has its management philosophy and will to pursue sustainable management as its strength based on the leadership of its CEO,” and added, “Since 2017, ‘Trust Management’ has been the management slogan, and from 2022, ‘Trust Management’ has been used as a management slogan. The efforts that have been made consistently, such as reflecting ‘sustainable innovation management’ in the management policy, indicate that the CEO clearly recognizes that ‘the sustainable growth of a company is based on fulfilling social responsibilities and coexistence with stakeholders.’ “It is judged,” he said.
President Park Jae-hyun said, “Hanmi Pharmaceuticals is achieving substantial growth every year based on unwavering R&D and sustainable management.” He added, “Achieving solid management performance and maximizing corporate value is a way to repay the generous support and trust of our stakeholders.” “Keeping in mind that this is the only way, we will continue to play a leading role in the Korean healthcare industry by focusing on developing globally recognized innovative new drugs for obesity metabolism, anti-cancer, and rare diseases,” he said.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
